Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912925 · ClinicalTrials.gov registry record · Phase 3
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT00912925 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 45 participants.
The verdict
NCT00912925, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL rhIDU (recombinant human-Alpha-L-Iduronidase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2000-12 |
| Est. Completion | 2001-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912925
The ClinicalTrials.gov registry entry for NCT00912925 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00912925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912925 about?
NCT00912925 is a clinical study titled "Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I". This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients
What is the current status of trial NCT00912925?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2000-12. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00912925?
The interventions under investigation include: Placebo (BIOLOGICAL), rhIDU (recombinant human-Alpha-L-Iduronidase) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00912925?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.